KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2025)

Historic Operating Leases for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q3 2025 value amounting to $192.8 million.

  • CRISPR Therapeutics AG's Operating Leases fell 849.42% to $192.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.8 million, marking a year-over-year decrease of 849.42%. This contributed to the annual value of $206.4 million for FY2024, which is 744.46% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Operating Leases stood at $192.8 million for Q3 2025, which was down 849.42% from $197.4 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Operating Leases' 5-year high stood at $234.2 million during Q2 2022, with a 5-year trough of $49.4 million in Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Operating Leases had a median value of $214.9 million in 2024 and averaged $205.2 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Operating Leases surged by 39969.92% in 2021 and then tumbled by 849.42% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Leases (Quarter) stood at $212.9 million in 2021, then rose by 7.19% to $228.2 million in 2022, then decreased by 2.27% to $223.0 million in 2023, then dropped by 7.44% to $206.4 million in 2024, then fell by 6.61% to $192.8 million in 2025.
  • Its Operating Leases was $192.8 million in Q3 2025, compared to $197.4 million in Q2 2025 and $201.9 million in Q1 2025.